These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 10146987)

  • 21. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.
    Deicher R; Hörl WH
    Drugs; 2004; 64(5):499-509. PubMed ID: 14977387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
    Nicholas JC
    Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epoetin alfa: clinical trial therapy.
    ANNA J; 1989 Aug; 16(5):344-8. PubMed ID: 2673077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications.
    Markham A; Bryson HM
    Drugs; 1995 Feb; 49(2):232-54. PubMed ID: 7729331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Should the hematocrit be normalized in dialysis and in pre-ESRD patients?
    Macdougall IC
    Blood Purif; 2001; 19(2):157-67. PubMed ID: 11150803
    [No Abstract]   [Full Text] [Related]  

  • 29. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
    Demetri GD
    Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):31-7. PubMed ID: 11308272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case management of the anemic patient: epoetin alfa--focus on cognitive function.
    Corea AL
    ANNA J; 1993 Jun; 20(3):350-3. PubMed ID: 8352632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epoetin: human recombinant erythropoietin.
    Flaharty KK; Grimm AM; Vlasses PH
    Clin Pharm; 1989 Nov; 8(11):769-82. PubMed ID: 2680241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.
    Frampton JE; Faulds D
    Pharmacoeconomics; 1993 Nov; 4(5):366-95. PubMed ID: 10146875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case management of the anemic patient. Epoetin alfa: focus on quality of life.
    Butera E
    ANNA J; 1992 Aug; 19(4):410-1. PubMed ID: 1520032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
    Kimel M; Leidy NK; Mannix S; Dixon J
    Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients.
    Courtney AE; McNamee PT; Maxwell AP
    Nephron Clin Pract; 2007; 107(1):c14-9. PubMed ID: 17664890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.
    Gabrilove JL; Cleeland CS; Livingston RB; Sarokhan B; Winer E; Einhorn LH
    J Clin Oncol; 2001 Jun; 19(11):2875-82. PubMed ID: 11387360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.
    Faulds D; Sorkin EM
    Drugs; 1989 Dec; 38(6):863-99. PubMed ID: 2693045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.